ObsEva SA (SIX: OBSN) is thrilled to announce that it has regained full exclusive global rights to nolasiban, a revolutionary oral oxytocin receptor antagonist that can substantially improve clinical pregnancy and live birth rates in women undergoing IVF treatments. This comes after the termination of the sub-licensing agreement with Yuyuan BioScience. This revolutionary treatment is set to revolutionize the fertility industry, bringing new hope to families around the world.
ObsEva recently granted Yuyuan an exclusive sublicense to use, register, and market nolasiban for use in humans in the People’s Republic of China, including Hong Kong and Macau. However, due to Yuyuan’s failure to meet requireddevelopment milestones within set deadlines, ObsEva terminated the agreement and reclaimed the license rights on nolasiban on July 12, 2023.
ObsEva is thrilled to be regaining its foothold in the reproductive health market in China, with the return of its nolasiban rights. As the global leader in one third of ART cycles, the Chinese market presents a huge opportunity to address the unmet medical need in IVF and capitalize on its commercial potential.
Nolasiban’s efficacy results from existing trial data are promising and show meaningful gains in pregnancy rates, without any concerning safety hazards. We look forward to continuing its clinical development and exploring potential strategic partnerships with established players.
ObsEva has demonstrated in its clinical trials of nolasiban, involving over 1,700 patients, an average 5.03% absolute (15% relative) increase versus placebo in the 10 weeks ongoing pregnancy rate after embryo transfer following IVF.
This increase was considered clinically significant by IVF specialists and could potentially have a meaningful effect on the success rates of ART cycles, of which 3.1 million were conducted worldwide in 2018. Moreover, the safety profile of nolasiban is favorable, making it a promising treatment option for those struggling with infertility.
ObsEva, a biopharmaceutical company, is on a mission to revolutionize women’s reproductive health and pregnancy with its cutting-edge therapies. Through its dedicated development program, ObsEva seeks to improve in vitro fertilization success rates, bringing couples closer to achieving their dream of parenthood. The company is listed on the SIX Swiss Exchange with ticker symbol “OBSN”, making its innovative therapies accessible to those who need it most.